Company profile: Femasys
1.1 - Company Overview
Company description
- Provider of medical device R&D and manufacturing for women’s healthcare, offering FemCerv, an FDA-cleared endocervical sampler; FemBloc, a nonsurgical in-office procedure for permanent contraception via fallopian tube blockage with a biopolymer using a proprietary delivery platform; and FemVue, an FDA-cleared product for real-time fallopian tube evaluation using saline and air contrast with ultrasound in a GYN’s office.
Products and services
- FemBloc: A proprietary nonsurgical, in-office procedure that blocks the fallopian tubes using a biopolymer delivered via a dedicated platform for permanent contraception
- FemCerv: An FDA-cleared endocervical sampler engineered to capture a complete, uncontaminated cervical cell and tissue specimen in a relatively pain-free office procedure
- FemVue: An FDA-cleared product enabling real-time fallopian tube evaluation by combining natural saline and air contrast with ultrasound, allowing comprehensive exams in a GYN’s office
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Femasys
BiVictriX Therapeutics
HQ: United Kingdom
Website
- Description: Provider of oncology and haematological malignancy drug discovery and development, biotherapeutics, immunotherapy, and antibody research, specializing in bispecific ADC therapeutics. Offers BVX001, a bispecific ADC targeting CD33/CD7 for Acute Myeloid Leukaemia (AML), and Bi-Cygni Therapeutics, targeting cancer-specific antigen pairs to improve selectivity and reduce toxicity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BiVictriX Therapeutics company profile →
Intradigm
HQ: United States
Website
- Description: Provider of RNA interference (RNAi) therapeutics for the treatment of serious diseases, with an initial focus on oncology. The private biotechnology company leverages drug development and delivery expertise as the foundation of its RNAi platform, including a proprietary RNAi Nanoplex delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intradigm company profile →
Pharmacyclics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmacyclics company profile →
CG Oncology
HQ: United States
Website
- Description: Provider of clinical-stage oncolytic immunotherapies targeting cancer, centered on the investigational agent cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Activities include Phase 3 trials BOND-003 (monotherapy in high-risk BCG-unresponsive NMIBC) and PIVOT-006 (intermediate-risk NMIBC), and the Phase 2 CORE-001 combination with pembrolizumab in high-risk BCG-unresponsive NMIBC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CG Oncology company profile →
Kronos Bio
HQ: United States
Website
- Description: Provider of oncology therapies that modulate historically undruggable cancer targets. Pipeline includes KB-0742, a CDK9 inhibitor in phase 1/2 for MYC-dependent tumors, and KB-9558 targeting the p300 KAT domain for multiple myeloma. Offers a Small Molecule Microarray screening platform for transcription factor binding assays and a discovery collaboration with Genentech.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kronos Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Femasys
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Femasys
2.2 - Growth funds investing in similar companies to Femasys
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Femasys
4.2 - Public trading comparable groups for Femasys
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →